Recon: Senate report says AbbVie sheltered profits from US taxes; Merck in talks to acquire Seagen for $40B

• Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug (Endpoints) (STAT) (Reuters)
• Senate Report Hits AbbVie’s Bermuda Tax Structure for U.S. Humira Sales (WSJ) (Washington Post)
• Mylan Pharmaceuticals faces another recall on insulin injection pens (Endpoints)
• US government warns health and pharma companies after series of ransomware attacks (Endpoints)
• U.S. FDA allows pharmacists to prescribe Pfizer's COVID-19 pill (Reuters) (Bloomberg)
• Drug Price War Gets Agency Buy-Ins as Senate Democrats Push Plan (Bloomberg)
• In the search for an ARPA-H director, the White House is zeroing in on DARPA veterans (STAT)
• As new monkeypox cases spike globally, Labcorp rolls out first national lab test (Endpoints)
• Democrats Plan to Extend Medicare Solvency in New Biden Bill (Bloomberg)
• Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need (STAT)

• EU drugs regulator open to COVID boosters that target older Omicron offshoots (Reuters)
• Pace Of Omicron Variants Hindering Work On Adapted COVID-19 Vaccines (The Pink Sheet)
• Germany: Leaked Pricing Measures Could Have ‘Drastic’ Consequences For Orphans (The Pink Sheet)
• WHO reports two new monkeypox deaths, cases in new areas (Reuters)
• Slovakia confirms first case of monkeypox -public health authority (Reuters)
• WTO faces new battle over COVID tests, drugs (Reuters)
• Africa CDC says it has signed MOU with Pfizer for COVID pill (Reuters)

• Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More (WSJ) (Biospace)
• Diamedica Sinks as FDA Places Clinical Hold on ReMEDy2 Trial (Bloomberg)
• Skyhawk Teams With Sanofi on Oncology and Immunology Targes in Deal Worth Potentially $2 Billion (FDANews)
• GSK's consumer health spinoff Haleon preps launch with $12B+ in debt (Endpoints)
• Sarepta, Roche Tout Promising Data for Muscular Dystrophy Gene Therapy (Biospace)
• Legend scraps early stage CAR-T for lymphoma 6 weeks after clinical hold lifted (Fierce)
• As ALS patients unite around Amylyx, a new paper hints at potential druggable targets (Endpoints)
• ‘Unconscious biases’ and lack of trust lead to gaps in routine healthcare for LGBTQ+ community — study (Endpoints)

• European Commission Expects Eudamed To Be Fully Ready By Q2 2024 (MedTech Insight)
• SD Biosensor agrees to buy Meridian Bioscience for $1.53B in bid to enter U.S. IVD market (MedTech Dive)
• Cracked, Broken Power Switches Lead To Class I Recall For Getinge Anesthesia Systems (MedTech Insight) (MedTech Dive)
• DeHealth Applies Blockchain To Medical Data Transactions In Bid For Transparency (MedTech Insight)
• Insilico Medicine’s AI uncovers 28 new potential targets for ALS (Fierce)
• Pfizer acquisition target ResApp reels in FDA nod for iPhone app to detect sleep apnea (Fierce)

• AstraZeneca Loses Bid to Dismiss Seroquel Pay-for-Delay Lawsuits (Bloomberg)
• Teladoc, Amwell Settle Patent Suit on Remote Health-Care Tech (Bloomberg)
• Jury Finds Endo Pharmaceuticals’ Pay-for-Delay Deal Didn’t Break Antitrust Laws (FDAnews)